These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
271 related articles for article (PubMed ID: 26824277)
41. Discovery, optimization, and evaluation of non-bile acid FXR/TGR5 dual agonists. Miyata S; Kawashima Y; Sakai M; Matsubayashi M; Motoki K; Miyajima Y; Watanabe Y; Chikamatsu N; Taniguchi T; Tokuyama R Sci Rep; 2021 Apr; 11(1):9196. PubMed ID: 33911126 [TBL] [Abstract][Full Text] [Related]
42. Beneficial effects of bile acid receptor agonists in pulmonary disease models. Comeglio P; Morelli A; Adorini L; Maggi M; Vignozzi L Expert Opin Investig Drugs; 2017 Nov; 26(11):1215-1228. PubMed ID: 28949776 [TBL] [Abstract][Full Text] [Related]
43. Discovery of new non-steroidal farnesoid X receptor modulators through 3D shape similarity search and structure-based virtual screening. Wang L; Si P; Sheng Y; Chen Y; Wan P; Shen X; Tang Y; Chen L; Li W Chem Biol Drug Des; 2015 Apr; 85(4):481-7. PubMed ID: 25228339 [TBL] [Abstract][Full Text] [Related]
44. Molecular field analysis and 3D-quantitative structure-activity relationship study (MFA 3D-QSAR) unveil novel features of bile acid recognition at TGR5. Macchiarulo A; Gioiello A; Thomas C; Massarotti A; Nuti R; Rosatelli E; Sabbatini P; Schoonjans K; Auwerx J; Pellicciari R J Chem Inf Model; 2008 Sep; 48(9):1792-801. PubMed ID: 18698841 [TBL] [Abstract][Full Text] [Related]
45. Farnesoid X receptor: from medicinal chemistry to clinical applications. Fiorucci S; Mencarelli A; Distrutti E; Zampella A Future Med Chem; 2012 May; 4(7):877-91. PubMed ID: 22571613 [TBL] [Abstract][Full Text] [Related]
46. New insights in the multiple roles of bile acids and their signaling pathways in metabolic control. de Boer JF; Bloks VW; Verkade E; Heiner-Fokkema MR; Kuipers F Curr Opin Lipidol; 2018 Jun; 29(3):194-202. PubMed ID: 29553998 [TBL] [Abstract][Full Text] [Related]
47. Development of bile acid activated receptors hybrid molecules for the treatment of inflammatory and metabolic disorders. Fiorucci S; Sepe V; Biagioli M; Fiorillo B; Rapacciuolo P; Distrutti E; Zampella A Biochem Pharmacol; 2023 Oct; 216():115776. PubMed ID: 37659739 [TBL] [Abstract][Full Text] [Related]
48. ENDOCRINOLOGY IN PREGNANCY: Metabolic impact of bile acids in gestation. Fan HM; Mitchell AL; Williamson C Eur J Endocrinol; 2021 Mar; 184(3):R69-R83. PubMed ID: 33434155 [TBL] [Abstract][Full Text] [Related]
49. Anthranilic acid derivatives as novel ligands for farnesoid X receptor (FXR). Merk D; Gabler M; Gomez RC; Flesch D; Hanke T; Kaiser A; Lamers C; Werz O; Schneider G; Schubert-Zsilavecz M Bioorg Med Chem; 2014 Apr; 22(8):2447-60. PubMed ID: 24685112 [TBL] [Abstract][Full Text] [Related]
50. Structural Insight into the Binding Mode of FXR and GPBAR1 Modulators. Di Leva FS; Di Marino D; Limongelli V Handb Exp Pharmacol; 2019; 256():111-136. PubMed ID: 31161298 [TBL] [Abstract][Full Text] [Related]
51. Modification on ursodeoxycholic acid (UDCA) scaffold. discovery of bile acid derivatives as selective agonists of cell-surface G-protein coupled bile acid receptor 1 (GP-BAR1). Sepe V; Renga B; Festa C; D'Amore C; Masullo D; Cipriani S; Di Leva FS; Monti MC; Novellino E; Limongelli V; Zampella A; Fiorucci S J Med Chem; 2014 Sep; 57(18):7687-701. PubMed ID: 25162837 [TBL] [Abstract][Full Text] [Related]
52. Development of Selective TGR5 Ligands Based on the 5,6,7,8-Tetrahydro-5,5,8,8-tetramethylnaphthalene Skeleton. Terui R; Yanase Y; Yokoo H; Suhara Y; Makishima M; Demizu Y; Misawa T ChemMedChem; 2021 Feb; 16(3):458-462. PubMed ID: 32969181 [TBL] [Abstract][Full Text] [Related]
53. Bile acid derivatives as ligands of the farnesoid x receptor: molecular determinants for bile acid binding and receptor modulation. Gioiello A; Cerra B; Mostarda S; Guercini C; Pellicciari R; Macchiarulo A Curr Top Med Chem; 2014; 14(19):2159-74. PubMed ID: 25388535 [TBL] [Abstract][Full Text] [Related]
54. Metabolic effects of bile acid sequestration: impact on cardiovascular risk factors. Spinelli V; Chávez-Talavera O; Tailleux A; Staels B Curr Opin Endocrinol Diabetes Obes; 2016 Apr; 23(2):138-44. PubMed ID: 26859552 [TBL] [Abstract][Full Text] [Related]
55. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Watanabe M; Houten SM; Mataki C; Christoffolete MA; Kim BW; Sato H; Messaddeq N; Harney JW; Ezaki O; Kodama T; Schoonjans K; Bianco AC; Auwerx J Nature; 2006 Jan; 439(7075):484-9. PubMed ID: 16400329 [TBL] [Abstract][Full Text] [Related]
56. Design, synthesis and biological evaluations of novel farnesoid X receptor (FXR) agonists. Zhu Y; Zhang J; Min F; Yang X; Li L; Zhang Y; Hou X; Fang H Bioorg Med Chem Lett; 2022 Nov; 76():128993. PubMed ID: 36130662 [TBL] [Abstract][Full Text] [Related]
57. Discovery and SAR study of 3-(tert-butyl)-4-hydroxyphenyl benzoate and benzamide derivatives as novel farnesoid X receptor (FXR) antagonists. Song K; Xu X; Liu P; Chen L; Shen X; Liu J; Hu L Bioorg Med Chem; 2015 Oct; 23(19):6427-36. PubMed ID: 26337021 [TBL] [Abstract][Full Text] [Related]
58. The role of bile salts in liver regeneration. van de Laarschot LF; Jansen PL; Schaap FG; Olde Damink SW Hepatol Int; 2016 Sep; 10(5):733-40. PubMed ID: 27048617 [TBL] [Abstract][Full Text] [Related]
59. Progress and challenges of selective Farnesoid X Receptor modulation. Massafra V; Pellicciari R; Gioiello A; van Mil SWC Pharmacol Ther; 2018 Nov; 191():162-177. PubMed ID: 29933033 [TBL] [Abstract][Full Text] [Related]
60. Bile acid-stimulated expression of the farnesoid X receptor enhances the immune response in Barrett esophagus. Capello A; Moons LM; Van de Winkel A; Siersema PD; van Dekken H; Kuipers EJ; Kusters JG Am J Gastroenterol; 2008 Jun; 103(6):1510-6. PubMed ID: 18510604 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]